Patents Assigned to Imperial Cancer Research Technology Ltd.
-
Patent number: 6608053Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.Type: GrantFiled: April 26, 2001Date of Patent: August 19, 2003Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
-
Patent number: 6576237Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vetebrate tissue both in vitro and in vivo.Type: GrantFiled: August 16, 2000Date of Patent: June 10, 2003Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
-
Patent number: 6403588Abstract: The present invention relates to novel compounds having a phosphatidylinositol 3 kinase (PI3K) inhibiting activity which are useful as medicaments, more particularly as antitumor agent. Novel 3-(imidazo[1,2-a]pyridin-3-yl) derivatives or salts thereof exhibit an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity, and are thus useful as medicaments, especially as PI3K inhibitors and antitumor agents.Type: GrantFiled: April 26, 2001Date of Patent: June 11, 2002Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology, Ltd.Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Ken-Ichi Kawaguchi, Koyo Matsuda, Noriko Ishikawa, Tomonobu Koizumi, Mayumi Yamano, Minoru Okada, Mitsuaki Ohta
-
Patent number: 6384192Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: October 20, 1997Date of Patent: May 7, 2002Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
-
Patent number: 6271363Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: October 20, 1997Date of Patent: August 7, 2001Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
-
Patent number: 6262025Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: April 7, 1998Date of Patent: July 17, 2001Assignees: Imperial Cancer Research Technology, Ltd., Yale UnversityInventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
-
Patent number: 6165747Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: June 5, 1995Date of Patent: December 26, 2000Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
-
Patent number: 6004924Abstract: The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: March 6, 1996Date of Patent: December 21, 1999Assignees: Imperial Cancer Research Technology, Ltd., Yale UniversityInventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Anna Mary Myat, Robert J. Fleming, Spyridon Artavanis-Tsakonas, Robert S. Mann, Grace E. Gray
-
Patent number: 5869282Abstract: The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: March 7, 1995Date of Patent: February 9, 1999Assignees: Imperial Cancer Research Technology, Ltd., Yale UniversityInventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Anna Mary Myat, Robert J. Fleming, Spyridon Artavanis-Tsakonas, Robert S. Mann, Grace E. Gray
-
Patent number: 5683674Abstract: Antibodies which bind to the core protein of the human polymorphic epithelial mucin glycoprotein are useful in the diagnosis of cancer.Type: GrantFiled: June 5, 1995Date of Patent: November 4, 1997Assignee: Imperial Cancer Research Technology Ltd.Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
-
Patent number: 5441935Abstract: A 75-85 Kd glycopolypeptide, capable of acting as a receptor for polypeptide of the bombesin type, is isolated from the surface of Swiss 3T3 cells. Certain antagonists and antibodies to the glycopolypeptide are described, the antagonists being of quite different structure to bombesin e.g. .differential.D-Pro.sup.2 [-spantide, .differential.D-Phe.sup.5 [-spantide and position 5 variants thereof. The antagonists and antibodies are of interest medically in that they are able to influence cell proliferation that occurs under the influence of the bombesin-like polypeptides.Type: GrantFiled: September 3, 1992Date of Patent: August 15, 1995Assignee: Imperial Cancer Research Technology Ltd.Inventors: Enrique Rozengurt, Ian Zachary, Penella Woll
-
Patent number: 5434132Abstract: Oligopeptides have been found that antagonist cell proliferation stimulated not only by bombesin-like peptides but also other neuropeptides e.g. vasopressin and bradykinin. These oligopeptides block a broad family of mitogenic neuropeptides that bind to receptors that use the inositol signalling pathway and one such receptor has been identified. These oligopeptides are of particular interest in relation to small cell lung cancer.Type: GrantFiled: November 2, 1993Date of Patent: July 18, 1995Assignee: Imperial Cancer Research Technology, Ltd.Inventors: Enrique Rozengurt, Penella Woll
-
Patent number: 5098823Abstract: A nucleic acid fragment capable of selectively hybridizing with the human chromosome 5 at the chromosomal region 5q20-q23 is disclosed. Also disclosed are probes which include the fragment bearing a detectable level as well as processes for presymptomatic screening for FAP and processes for the pathological classification of colonic tumors and precancerous polyps.Type: GrantFiled: April 12, 1990Date of Patent: March 24, 1992Assignee: Imperial Cancer Research Technology Ltd.Inventors: Walter F. Bodmer, Victoria A. Murday, Carolyn J. Bailey, Robert Williamson